Glucose-6-phosphate dehydrogenase deficiency protects against coronary heart disease

Journal of Inherited Metabolic Disease

Volumn 31, Issue 3, 2008, Pages 412-417

  Meloni, L ^a   Manca, M R ^a   Loddo, I ^a   Cioglia, G ^a   Cocco, P ^a   Schwartz, A ^b   Muntoni, S ^c   Muntoni, Sa ^a,c  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Centre For Metabolic Diseases and Atherosclerosis   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE 6 PHOSPHATE DEHYDROGENASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; OXYGEN RADICAL; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE PREDISPOSITION; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME REGULATION; ERYTHROCYTE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE DEFICIENCY; HEART PROTECTION; HUMAN; ISCHEMIC HEART DISEASE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; RISK REDUCTION; UNSTABLE ANGINA PECTORIS; WILD TYPE;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CORONARY DISEASE; FREE RADICALS; GLUCOSEPHOSPHATE DEHYDROGENASE DEFICIENCY; HUMANS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; LOGISTIC MODELS; MALE; MIDDLE AGED; NADPH OXIDASE;

EID: 45849139648     PISSN: 01418955     EISSN: 15732665     Source Type: Journal    
DOI: 10.1007/s10545-008-0704-5     Document Type: Article

References (45)

1. Babior BM (1999) NADPH oxidase: An update. Blood 93: 1464-1476.
2. Battistuzzi G, D'Urso M, Toniolo D, Persico GM, Luzzatto L (1985) Tissue-specific levels of human glucose 6-phosphate dehydrogenase correlate with methylation of specific sites at the 3′ end of the gene. Proc Natl Acad Sci USA 82: 465-469.
3. Beutler E (1991) Glucose-6-phosphate dehydrogenase deficiency. N Engl J Med 324: 169-174.
4. Bilmen S, Aksu TA, Gümüşlü S, Korgun DK, Canatan D (2001) Antioxidant capacity of G-6-PD-deficient erythrocytes. Clin Chim Acta 303: 83-86.
5. Blackburn H (1991) The potential for prevention of atherosclerosis in children. Ann N Y Acad Sci 623: 2-8.
6. Cannon CP, Braunwald E, McCabe CH et al for the Pravastatin or Atorvastatin Evaluation and Infection Therapy - Thrombolysis in Myocardial Infarction 22 Investigators (2004) Intensive versus moderate lipid lowering with statins after acute coronary syndrome. N Engl J Med 350: 1495-1504.
7. Cathcart MK (2004) Regulation of superoxide anion production by NADPH oxidase in monocyte/macrophages: Contribution to atherosclerosis. Arterioscl Thromb Vasc Biol 24: 23-28.
8. Cavalli Sforza LL, Piazza A (1993) Human genomic diversity in Europe: A summary of recent research and prospects for the future. Eur J Hum Gen 1: 3-18.
9. Chan TK, Todd W, Wong CC (1965) Tissue enzyme levels in erythrocyte glucose 6-phosphate dehydrogenase deficiency. J Lab Clin Med 66: 937-942.
10. Cocco P, Manca P, Dessì S (1987) Preliminary results of a geographic correlation study on G6PD deficiency and cancer. Toxicol Pathol 15: 106-108.
11. Cocco P, Todde P, Fornera S, Manca MB, Manca P, Sias R (1998) Mortality in a cohort of men expressing the glucose 6-phosphate dehydrogenase deficiency. Blood 91: 706-709.
12. Comparato C, Altana C, Bellosta S, Baetta R, Paoletti R, Corsini A (2001) Clinically relevant pleiotropic effects of statins: Drug properties or effects of profound cholesterol reduction? Nutr Metab Cardiovasc Dis 11: 328-343.
13. De Vita G, Alcalay M, Sampietro M, Cappellini MD, Fiorelli G, Toniolo D (1989) Two point mutations are responsible for G6PD polymorphism in Sardinia. Am J Hum Genet 44: 233-240.
14. Downs JR, Clearfield M, Weis S et al (1998) Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. JAMA 279: 1615-1622.
15. Endres M (2006) Statins. Potential new indications in inflammatory conditions. Atherosclerosis Supplements 7: 31-35.
16. Feron O, Dessy C, Moniotte S (1999) Hypercholesterolemia decreases nitric oxide production by promoting the interaction of caveolin and endothelial nitric oxide synthase. J Clin Invest 103: 897-905.
17. Filosa S, Calabrò V, Lania G, et al (1993) G6PD haplotypes spanning Xq28 from F8C to red/green color vision. Genomics 17: 6-14.
18. Fortuño A, San José G, Moreno MU, Beloqui O, Dìez J, Zalba G (2006) Phagocytic NADPH oxidase overactivity underlies oxidative stress in metabolic syndrome. Diabetes 55: 209-215.
19. Gimbrone MA, Kume N, Cibulsky M (1993) Vascular endothelial dysfunction and the pathogenesis of atherosclerosis. In: Weber P, Leaf A, eds. Atherosclerosis Reviews. New York: Raven Press, 25, 1-9.
20. Goldstein JL, Brown MS (1990) Regulation of the mevalonate pathway. Nature 343: 425-430.
21. Gorog DA, Rakhit R, Parums D, Laffan M, Davies GJ (1998) Raised factor VIII is associated with coronary thrombotic events. Heart 80: 415-417.
22. Istvan ES, Deisenhofer J (2001) Structural mechanism for statin inhibition of HMG-CoA reductase. Science 292: 1160-1164.
23. Kirkman HN (1968) Glucose 6-phosphate dehydrogenase variants and the drug-induced hemolysis. Ann N Y Acad Sci 151: 753-764.
24. Kornberg A, Horeker BL, Smyrniotis PZ (1955) Glucose 6-phosphate dehydrogenase. In: Methods in Enzymology. New York, Academic Press, 323-327.
25. Leopold JA, Cap A, Scribner AW, Stanton R, Loscalzo J (2001) Glucose 6-phosphate dehydrogenase deficiency promotes endothelial oxidative stress and decreases endothelial nitric oxide bioavailability. FASEB J 15: 1771-1773.
26. Long WK, Wilson SW, Frenkel EP (1967) Association between red cell glucose 6-phosphate variants and vascular disease. Am J Hum Genet 19: 35-53.
27. Luzzatto L, Mehta A, Vulliamy T (2001) Glucose 6-phosphate dehydrogenase deficiency. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds; Childs B, Kinzler KW, Vogelstein B, assoc. eds. The Metabolic and Molecular Bases of Inherited Disease, 8th edn. New York: McGraw-Hill, 4517-4553.
28. Matsui R, Xu S, Maitland KA, et al (2005) Glucose-6 phosphate dehydrogenase deficiency decreases the vascular response to angiotensin II. Circulation 112: 257-263.
29. Matsui R, Xu S, Maitland KA, et al (2006) Glucose-6 phosphate dehydrogenase deficiency decreases vascular superoxide anion and atherosclerotic lesions in Apoliporotein E -/- mice. Arterioscler Thromb Vasc Biol 26: 910-916.
30. Moncada S, Palmer RMJ, Higgs EA (1991) Nitric oxide: Physiology, pathophysiology, and pharmacology. Pharmacol Rev 43: 109-142.
31. Muntoni S (2003) G-6-PD deficiency: A naturally-occurring model of HMG-CoA reductase restraint. Ann Nutr Metab 47: 229-254 (Abstract, pp. 241-242).
32. Muntoni S, Muntoni Sa (2001) Genetic influences on serum LDL levels and type 1 diabetes incidence in Sardinia. In: Simopulos AP, Pavlou KN, eds. Nutrition and Fitness: Diet, Genes, Physical Activity and Health. Basel: Karger, 89, 76-82.
33. Muntoni S, Batetta B, Dessì S, Muntoni Sa, Pani P (1992) Serum lipoprotein profile in the Mediterranean variant of glucose 6-phosphate dehydrogenase deficiency. Eur J Epidemiol 8(Supplement 1): 48-53.
34. Nikolaidis MG, Jamurtas AZ, Paschalis V, et al (2006) Exercise-induced oxidative stress in G6PD-deficient individuals. Med Sci Sports Exerc 28: 1443-1450.
35. Oluboyede OA, Esan GJF, Francis TI, Luzzatto L (1979) Genetically determined deficiency of glucose 6-phosphate dehydrogenase (type A-) is expressed in the liver. J Lab Clin Med 93: 783-789.
36. Park J, Choe SS, Choi AH, et al (2006) Increase in glucose-6-phosphate dehydrogenase in adipocytes stimulates oxidative stress and inflammatory signals. Diabetes 55: 2939-2949.
37. Sanna E, Bruno R, Cosseddu GG, Floris G, Salis A, Silvetti M (1990) Present-day G-6-PD deficit in Sardinia with respect to malarial morbidity and mortality in the past. Z Morph Anthrop 70: 257-267.
38. Scandinavian Simvastatin Survival Study (4S) (1997) Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 344: 1383-1389.
39. Schwartz AG, Pashko LL (2004) Dehydroepiandrosterone, glucose-6-phosphate dehydrogenase, and longevity. Ageing Res Rev 3: 171-187.
40. Sheperd J, Cobbe SM, Ford I, et al for the West of Scotland Coronary Prevention Study Group (1995) Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 333: 1301-1307.
41. Siniscalco M, Bernini L, Latte B, Motulski G (1961) Favism and thalassemia and their relationship to malaria. Nature 190: 1179-1180.
42. Siperstein MD (1984) Role of cholesterogenesis and isoprenoid synthesis in DNA replication and cell growth. J Lipid Res 25: 1462-1468.
43. Wattanasuwan N, Khan IA, Gowda RM, Vasavada BC, Sacchi TJ (2001) Effect of acute myocardial infarction on cholesterol ratios. Chest 120: 1196-1199.
44. Zalba G, Beloqui O, San José G, Moreno MU, Fortugño A, Diez J (2005) NADPH oxidase-dependent superoxide production is associated with carotid intima-media thickness in subjects free of clinical atherosclerotic disease. Arterioscler Thromb Vasc Biol 25: 1452-1457.
45. Zeiher AM (1996) Endothelial vasodilator dysfunction: Pathogenetic link to myocardial ischaemia or epiphenomenon? Lancet 348(Supplement I): s10-s12.